东方生物：公司及子公司取得多项医疗器械注册证

Core Viewpoint - The company and its subsidiaries have obtained multiple medical device registration certificates, which will enhance product variety and facilitate market expansion, although the actual sales performance remains uncertain [1] Group 1: Product Registration - The company and its wholly-owned subsidiary, Shanghai Wanzijian Biotechnology, have received registration certificates for various medical devices, including inflammation marker detection kits and COVID-19/FluA&B antigen combined test kits [1] - The registration includes self-testing kits and rapid antigen tests for FluA&B, RSV, and Adenovirus [1] Group 2: Market Impact - The acquisition of these registration certificates is expected to enrich the company's product offerings, aiding in market expansion [1] - However, the actual sales performance will depend on product competitiveness and market sales capabilities, making it difficult to predict the impact on future operating performance [1]